【摘要】 目的研究多奈哌齐治疗我国轻中度阿尔茨海默病(AD)患者的疗效和安全性。方法将48例轻中度AD患者随机均分为两组,用多奈吸哌齐和卡巴拉汀治疗16周。采用简易精神状态量表(MMSE)、Blessed-Roth量表和总体衰退量表(GDS)评定疗效。安全性检查包括生命体征,实验室及心电图检查,每4周1次。结果两组治疗前后MMSE,GDS和Blessed-Roth评分均有显著改善(P<0.05)。但两组治疗前后相关量表总分差值的t检验均无显著意义(P>0.05)。两组治疗前后Blessed-Roth各亚项分数差值比较无显著性(P>0.05)。不良反应为胃肠道反应,发生率在15.0%~29.5%之间,以卡巴拉汀组多见。结论多奈吸哌齐和卡巴拉汀可显著改善AD患者的认知功能、痴呆程度和日常生活能力,疗效相当,较为安全,耐受性较好。更多还原

【Abstract】 Objectives: To study the efficacy and safety of donepezil in the treatment of patients with mild to moderate Alzheimer′s disease (AD) in our country. Methods: 48 cases with mild to moderate AD were divided into two groups randomly and treated bydonepezil and rivastigmine, respectively. Mini Mental State Examination (MMSE), Blessed-Routh Rating Scale (BRRS) and Global Deterioration Scale (GDS) were evaluated for efficacy, Vital signs, ECG and laboratorial tests were measured every 4 weeks for safety. Results: The scores of MMSE, GDS and BRRS in the two groups were improved greatly (P<0.05). But the difference of those scores between two groups at both baseline and end-point was not significant (P>0.05). Gastrointestinal reaction as adverse event occurred in 13.6%~29.5% patients in two groups and more commonly in rivastigmine treatment. Conclusion: Donepezil and rivastigmine both similarly improve cognitive ability, dementia degree and daily living ability in AD patients in our country and have generally well toleration and safety.更多还原